50.03Open50.03Pre Close0 Volume178 Open Interest190.00Strike Price0.00Turnover58.71%IV-1.98%PremiumDec 20, 2024Expiry Date54.89Intrinsic Value100Multiplier26DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type0.9568Delta0.0024Gamma4.36Leverage Ratio-0.0878Theta0.1274Rho4.17Eff Leverage0.0601Vega
Alnylam Pharmaceuticals Stock Discussion
Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024 | ALNY Stock News
ALNY BUY ALERT 🚨 DRUG NEWS MULTIPLE PRICE TARGET RAISES
No comment yet